

Recai Turkoglu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2262571/publications.pdf>

Version: 2024-02-01

68
papers

904
citations

471509

17
h-index

526287

27
g-index

73
all docs

73
docs citations

73
times ranked

1405
citing authors

#	ARTICLE	IF	CITATIONS
1	Fingolimod impairs inactivated vaccine (CoronaVac)-induced antibody response to SARS-CoV-2 spike protein in persons with multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 58, 103524.	2.0	8
2	Multiple Sclerosis Severity Score (MSSS) improves the accuracy of individualized prediction in MS. <i>Multiple Sclerosis Journal</i> , 2022, , 135245852210845.	3.0	2
3	Disability outcomes of early cerebellar and brainstem symptoms in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2021, 27, 755-766.	3.0	11
4	CSF levels of HoxB3 and YKL-40 may predict conversion from clinically isolated syndrome to relapsing remitting multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 48, 102697.	2.0	7
5	Cytokineâ€“chemokine and cognitive profile of multiple sclerosis patients with predominant optic nerve and spinal cord involvement. <i>Journal of Spinal Cord Medicine</i> , 2021, 44, 411-417.	1.4	5
6	Determinants of therapeutic lag in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2021, 27, 1838-1851.	3.0	3
7	Natalizumab, Fingolimod, and Dimethyl Fumarate Use and Pregnancy-Related Relapse and Disability in Women With Multiple Sclerosis. <i>Neurology</i> , 2021, 96, .	1.1	41
8	Utilization of Multiple Sclerosis Therapies in the Middle East Over a Decade: 2009â€“2018. <i>CNS Drugs</i> , 2021, 35, 1097-1106.	5.9	7
9	Peripheral blood B cell subset ratios and expression levels of B cell-associated genes are altered in benign multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 52, 103019.	2.0	5
10	The effectiveness of natalizumab vs fingolimodâ€“A comparison of international registry studies. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 53, 103012.	2.0	8
11	Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: A Subgroup Analysis From Three International Cohorts. <i>CNS Drugs</i> , 2021, 35, 1217-1232.	5.9	8
12	Long-term outcomes in patients presenting with optic neuritis: Analyses of the MSBase registry. <i>Journal of the Neurological Sciences</i> , 2021, 430, 118067.	0.6	9
13	miR-132-3p, miR-106b-5p, and miR-19b-3p Are Associated with Brain-Derived Neurotrophic Factor Production and Clinical Activity in Multiple Sclerosis: A Pilot Study. <i>Genetic Testing and Molecular Biomarkers</i> , 2021, 25, 720-726.	0.7	10
14	Safety and efficacy of teriflunomide in paediatric multiple sclerosis (TERIKIDS): a multicentre, double-blind, phase 3, randomised, placebo-controlled trial. <i>Lancet Neurology</i> , The, 2021, 20, 1001-1011.	10.2	36
15	Risk of secondary progressive multiple sclerosis: A longitudinal study. <i>Multiple Sclerosis Journal</i> , 2020, 26, 79-90.	3.0	52
16	Sleep disturbance and cognitive decline in multiple sclerosis patients with isolated optic neuritis as the first demyelinating event. <i>International Ophthalmology</i> , 2020, 40, 151-158.	1.4	4
17	Clinical and therapeutic predictors of disease outcomes in AQP4-IgG+ neuromyelitis optica spectrum disorder. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 38, 101868.	2.0	29
18	Expression of Akt1 and p-Akt1 in peripheral T cell subsets of multiple sclerosis patients. <i>Acta Neurologica Belgica</i> , 2020, 121, 1777-1782.	1.1	5

#	ARTICLE	IF	CITATIONS
19	Delay from treatment start to full effect of immunotherapies for multiple sclerosis. <i>Brain</i> , 2020, 143, 2742-2756.	7.6	24
20	Early clinical markers of aggressive multiple sclerosis. <i>Brain</i> , 2020, 143, 1400-1413.	7.6	32
21	Nivolumab-induced autoantibody negative limbic encephalitis in a patient with Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2020, 61, 1519-1521.	1.3	5
22	Impact of fingolimod on CD4+ T cell subset and cytokine profile of relapsing remitting multiple sclerosis patients. <i>Journal of Neuroimmunology</i> , 2019, 337, 577065.	2.3	9
23	Comparative analysis of fingolimod versus teriflunomide in relapsing-remitting multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 36, 101376.	2.0	4
24	Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, 458-468.	1.9	71
25	Incidence of pregnancy and disease-modifying therapy exposure trends in women with multiple sclerosis: A contemporary cohort study. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 28, 235-243.	2.0	35
26	Serum orexin-A levels are associated with disease progression and motor impairment in multiple sclerosis. <i>Neurological Sciences</i> , 2019, 40, 1067-1070.	1.9	19
27	Peripheral blood memory B cell frequency predicts conversion from clinically isolated syndrome to multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 23, 9-14.	2.0	8
28	Prevalence of and risk factors for cognitive impairment in patients with relapsing-remitting multiple sclerosis: Multi-center, controlled trial. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 22, 70-76.	2.0	37
29	PND39 - MULTIPLE SCLEROSIS BURDEN OF ILLNESS STUDY FOR TURKEY. <i>Value in Health</i> , 2018, 21, S335-S336.	0.3	0
30	Effects of computer-assisted cognitive rehabilitation in benign multiple sclerosis. <i>Turkish Journal of Medical Sciences</i> , 2018, 48, 999-1005.	0.9	5
31	Effects of in vivo and in vitro administration of neuro-Behçet's disease IgG. <i>Neurological Sciences</i> , 2017, 38, 833-843.	1.9	7
32	A NMOSD case with multifocal nervous system involvement in a single attack. <i>Multiple Sclerosis and Related Disorders</i> , 2017, 18, 82-84.	2.0	0
33	A Case of Seronegative Limbic Encephalitis with Multiple Sclerosis: A Possible Overlapping Syndrome. <i>American Journal of Case Reports</i> , 2017, 18, 64-66.	0.8	5
34	Recurrent tumefactive demyelinating lesions: a pathological study. , 2017, 36, 195-198.		5
35	Flow Cytometry Analysis of Peripheral Blood B Cell Distribution of Patients with Multiple Sclerosis. <i>Turk Noroloji Dergisi = Turkish Journal of Neurology</i> , 2017, 23, 219-224.	0.3	1
36	Limbic Encephalitis Associated with Sjögren's Syndrome: Report of Three Cases. <i>Internal Medicine</i> , 2016, 55, 2285-2289.	0.7	8

#	ARTICLE	IF	CITATIONS
37	Reduced fecal GABA levels in multiple sclerosis patients. <i>Multiple Sclerosis and Related Disorders</i> , 2016, 9, 60-61.	2.0	5
38	Expression of switch-associated protein 70 is associated with lymphocyte activation and reduced disability in multiple sclerosis. <i>Immunology Letters</i> , 2016, 177, 75-77.	2.5	1
39	Expression changes of genes associated with apoptosis and survival processes in Parkinsonâ€™s disease. <i>Neuroscience Letters</i> , 2016, 615, 72-77.	2.1	22
40	Serum Prolactin Levels in Multiple Sclerosis, Neuromyelitis Optica, and Clinically Isolated Syndrome Patients. <i>Noropsikiyatri Arsivi</i> , 2016, 53, 353-356.	0.7	5
41	Reduced serum vitamin D levels in neuromyelitis optica. <i>Neurological Sciences</i> , 2015, 36, 1701-1702.	1.9	11
42	The association between obesity and oligoclonal band formation in multiple sclerosis patients. <i>Obesity Research and Clinical Practice</i> , 2015, 9, 533-535.	1.8	4
43	Predictive value of early serum cytokine changes on long-term interferon beta-1a efficacy in multiple sclerosis. <i>International Journal of Neuroscience</i> , 2015, 125, 352-356.	1.6	4
44	Switch-Associated Protein 70 Antibodies in Multiple Sclerosis: Possible Association with Disease Progression. <i>Medical Principles and Practice</i> , 2014, 23, 239-245.	2.4	5
45	Aquaporin-1 Antibody in Neuromyelitis Optica Patients. <i>European Neurology</i> , 2014, 72, 271-272.	1.4	13
46	Sorcin antibody as a possible predictive factor in conversion from radiologically isolated syndrome to multiple sclerosis: a preliminary study. <i>Inflammation Research</i> , 2014, 63, 799-801.	4.0	5
47	A novel predictive factor, sorcin antibody in conversion of radiologically isolated syndrome to multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2014, 275, 17-18.	2.3	0
48	Short term fingolimod treatment decreases soluble VLA 4 levels in MS patients. <i>Journal of Neuroimmunology</i> , 2014, 275, 228.	2.3	0
49	Serum anti-neuronal antibodies in amyotrophic lateral sclerosis. <i>International Journal of Neuroscience</i> , 2013, 123, 557-562.	1.6	6
50	Glycine receptor and myelin oligodendrocyte glycoprotein antibodies in Turkish patients with neuromyelitis optica. <i>Journal of the Neurological Sciences</i> , 2013, 335, 221-223.	0.6	33
51	Anti-N-methyl-d-aspartate receptor encephalitis with minimal cortical impairment. <i>Neurological Sciences</i> , 2013, 34, 111-113.	1.9	7
52	Mitochondrial carrier homolog 1 (Mtch1) antibodies in neuro-Behçet's disease. <i>Journal of Neuroimmunology</i> , 2013, 263, 139-144.	2.3	17
53	Comparison of the Cytokine Profiles of Patients With Neuronal-Antibody-Associated Central Nervous System Disorders. <i>International Journal of Neuroscience</i> , 2012, 122, 284-289.	1.6	27
54	Effect of short-term interferon-Î² treatment on cytokines in multiple sclerosis: Significant modulation of IL-17 and IL-23. <i>Cytokine</i> , 2012, 59, 400-402.	3.2	37

#	ARTICLE	IF	CITATIONS
55	Isolated dysphagia due to aquaporin-4 autoimmunity. Turkish Journal of Gastroenterology, 2012, 23, 804-805.	1.1	3
56	Neurobrucellosis: clinical, diagnostic, therapeutic features and outcome. Unusual clinical presentations in an endemic region. Brazilian Journal of Infectious Diseases, 2011, 15, 52-59.	0.6	68
57	Atypical Presentation of Orbital Pseudotumor with Visual Loss as an Initial Manifestation. Journal of		